<![CDATA[TIP12 Validation of a Multimodal Artificial Intelligence Prognostic Model in Early-Stage HR+/HER2− Breast Cancer]]>

Trial StartMMAI prognostic modelPositive

AI Analysis

Summary

Artera's multimodal artificial intelligence prognostic model is being validated in early-stage HR+/HER2− breast cancer patients through the TIP12 study, with enrollment completion anticipated by April 2026. The model integrates digital pathology images with clinical data from H&E slides.

Clinical Trial Data

Importance:4/10

Sentiment:

0.30

breast cancerprognostic modelartificial intelligencedigital pathologyvalidation studyHR+/HER2−

Read the original article

Published by Cancer Network on July 11, 2026 10:30 PM

Read Original